STudy of Antithrombotic Treatment after IntraCerebral Haemorrhage: Protocol for a randomised controlled trial.
Intracerebral haemorrhage
anticoagulant
antiplatelet
antithrombotic treatment
atrial fibrillation
ischaemic events
randomised controlled trial
secondary prevention
stroke
Journal
European stroke journal
ISSN: 2396-9881
Titre abrégé: Eur Stroke J
Pays: England
ID NLM: 101688446
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
received:
13
05
2020
accepted:
29
07
2020
entrez:
18
2
2021
pubmed:
19
2
2021
medline:
19
2
2021
Statut:
ppublish
Résumé
Many patients with prior intracerebral haemorrhage have indications for antithrombotic treatment with antiplatelet or anticoagulant drugs for prevention of ischaemic events, but it is uncertain whether such treatment is beneficial after intracerebral haemorrhage. STudy of Antithrombotic Treatment after IntraCerebral Haemorrhage will assess (i) the effects of long-term antithrombotic treatment on the risk of recurrent intracerebral haemorrhage and occlusive vascular events after intracerebral haemorrhage and (ii) whether imaging findings, like cerebral microbleeds, modify these effects. STudy of Antithrombotic Treatment after IntraCerebral Haemorrhage is a multicentre, randomised controlled, open trial of starting versus avoiding antithrombotic treatment after non-traumatic intracerebral haemorrhage, in patients with an indication for antithrombotic treatment. Participants with vascular disease as an indication for antiplatelet treatment are randomly allocated to antiplatelet treatment or no antithrombotic treatment. Participants with atrial fibrillation as an indication for anticoagulant treatment are randomly allocated to anticoagulant treatment or no anticoagulant treatment. Cerebral CT or MRI is performed before randomisation. Duration of follow-up is at least two years. The primary outcome is recurrent intracerebral haemorrhage. Secondary outcomes include occlusive vascular events and death. Assessment of clinical outcomes is performed blinded to treatment allocation. Target recruitment is 500 participants.
Sections du résumé
BACKGROUND AND AIMS
OBJECTIVE
Many patients with prior intracerebral haemorrhage have indications for antithrombotic treatment with antiplatelet or anticoagulant drugs for prevention of ischaemic events, but it is uncertain whether such treatment is beneficial after intracerebral haemorrhage. STudy of Antithrombotic Treatment after IntraCerebral Haemorrhage will assess (i) the effects of long-term antithrombotic treatment on the risk of recurrent intracerebral haemorrhage and occlusive vascular events after intracerebral haemorrhage and (ii) whether imaging findings, like cerebral microbleeds, modify these effects.
METHODS
METHODS
STudy of Antithrombotic Treatment after IntraCerebral Haemorrhage is a multicentre, randomised controlled, open trial of starting versus avoiding antithrombotic treatment after non-traumatic intracerebral haemorrhage, in patients with an indication for antithrombotic treatment. Participants with vascular disease as an indication for antiplatelet treatment are randomly allocated to antiplatelet treatment or no antithrombotic treatment. Participants with atrial fibrillation as an indication for anticoagulant treatment are randomly allocated to anticoagulant treatment or no anticoagulant treatment. Cerebral CT or MRI is performed before randomisation. Duration of follow-up is at least two years. The primary outcome is recurrent intracerebral haemorrhage. Secondary outcomes include occlusive vascular events and death. Assessment of clinical outcomes is performed blinded to treatment allocation. Target recruitment is 500 participants.
Identifiants
pubmed: 33598560
doi: 10.1177/2396987320954671
pii: 10.1177_2396987320954671
pmc: PMC7856578
doi:
Types de publication
Journal Article
Langues
eng
Pagination
414-422Subventions
Organisme : Medical Research Council
ID : G1002605
Pays : United Kingdom
Organisme : British Heart Foundation
ID : PG/14/50/30891
Pays : United Kingdom
Organisme : British Heart Foundation
ID : FS/13/72/30531
Pays : United Kingdom
Organisme : British Heart Foundation
ID : CS/18/2/33719
Pays : United Kingdom
Organisme : British Heart Foundation
ID : SP/12/2/29422
Pays : United Kingdom
Informations de copyright
© European Stroke Organisation 2020.
Déclaration de conflit d'intérêts
Declaration of Conflicting Interests: The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: JP has served on a scientific advisory board for and received lecture fees from Bayer. CK has received lecture fees from Novo Nordic and Bristol-Myers Squibb Denmark. The other authors declare that they have no competing interests.
Références
Neurology. 2014 Mar 25;82(12):1020-6
pubmed: 24562060
Neurology. 2006 Jan 24;66(2):206-9
pubmed: 16434655
Stroke. 2014 Sep;45(9):2643-8
pubmed: 25082804
Chest. 2010 Nov;138(5):1093-100
pubmed: 20299623
Eur Stroke J. 2019 Sep;4(3):198-223
pubmed: 31984228
J Neurol Sci. 2018 Jan 15;384:133-138
pubmed: 29153510
Front Neurol. 2012 Sep 19;3:133
pubmed: 23015806
World Neurosurg. 2017 Oct;106:85-91
pubmed: 28606579
JAMA. 2015 Feb 24;313(8):824-36
pubmed: 25710659
Arch Neurol. 2008 Oct;65(10):1313-8
pubmed: 18852344
Lancet Neurol. 2007 Jun;6(6):487-93
pubmed: 17509483
Stroke. 2017 Jul;48(7):1810-1817
pubmed: 28596454
Ann Intern Med. 2007 Jun 19;146(12):857-67
pubmed: 17577005
Stroke. 2015 Jul;46(7):2032-60
pubmed: 26022637
Stroke. 2015 Aug;46(8):2094-9
pubmed: 26159794
Circulation. 2016 Apr 19;133(16):1540-7
pubmed: 26969761
Neurology. 2010 Aug 24;75(8):693-8
pubmed: 20733144
Lancet Neurol. 2019 Jul;18(7):643-652
pubmed: 31129065
Ann Neurol. 2017 Nov;82(5):755-765
pubmed: 29028130
Lancet. 2019 Jun 29;393(10191):2613-2623
pubmed: 31128924
Stroke. 2016 Jul;47(7):1837-43
pubmed: 27301947
Acta Neurol Scand. 2014 Apr;129(4):269-75
pubmed: 24444381
Neurology. 2017 Aug 15;89(7):687-696
pubmed: 28724590
Stroke. 2004 Jun;35(6):1415-20
pubmed: 15073385
Neurology. 2017 Aug 22;89(8):820-829
pubmed: 28747441
Thromb Haemost. 2012 Feb;107(2):241-7
pubmed: 22187066
Circulation. 2015 Aug 11;132(6):517-25
pubmed: 26059010
Thromb Haemost. 2017 Dec;117(12):2396-2405
pubmed: 29212127
Stroke. 2014 Jan;45(1):268-70
pubmed: 24203841
BMJ. 2002 Jan 12;324(7329):71-86
pubmed: 11786451
Int J Stroke. 2014 Oct;9(7):840-55
pubmed: 25156220
Stroke. 2017 Jun;48(6):1594-1600
pubmed: 28416626
J Neurol Neurosurg Psychiatry. 2014 Jun;85(6):660-7
pubmed: 24262916
Lancet Neurol. 2019 Jul;18(7):653-665
pubmed: 31130428
Stroke. 2010 Nov;41(11):2606-11
pubmed: 20947854
Stroke. 2010 Dec;41(12):2860-6
pubmed: 21030703
Neurology. 2007 Jan 9;68(2):116-21
pubmed: 17210891
Circulation. 2015 Aug 11;132(6):509-16
pubmed: 26137955
Brain. 2013 Feb;136(Pt 2):658-64
pubmed: 23378220
Chest. 2010 Feb;137(2):263-72
pubmed: 19762550
Lancet Neurol. 2010 Feb;9(2):167-76
pubmed: 20056489
Lancet. 2009 May 30;373(9678):1849-60
pubmed: 19482214
Stroke. 2019 May;50(5):1100-1107
pubmed: 31009357
Neurology. 2018 Jul 3;91(1):e26-e36
pubmed: 29848784
J Thromb Haemost. 2015 Nov;13(11):2119-26
pubmed: 26764429
Cochrane Database Syst Rev. 2017 May 25;5:CD012144
pubmed: 28540976
Lancet. 2014 Mar 15;383(9921):955-62
pubmed: 24315724
J Thromb Haemost. 2005 Apr;3(4):692-4
pubmed: 15842354
Can J Cardiol. 2012 Jan-Feb;28(1):33-9
pubmed: 22153256